optum cdm (Optum Inc)
86
Structured Review
Optum Inc
optum cdm
Optum Cdm, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optum+cdm/cdm+optum/pm42318627-39-0-0
Average 86 stars, based on 1 article reviews
Optum Cdm, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/optum+cdm/cdm+optum/pm42318627-39-0-0
Average 86 stars, based on 1 article reviews
optum cdm - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
other:Article Title: Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations. Article Snippet: Hospitalisation costs during the Article Title: Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations. Article Snippet: Derivative Assay:Article Title: Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations. Article Snippet: METHODS Study design and participants This was a retrospective cohort study of US patients hospitalised with a viral LRTD from 1 January 2015 to 31 March 2023 using Optum’s deidentified Clinformatics Data Mart Database (Optum CDM). .. Control:Article Title: Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023. Article Snippet: Background: Background incidence rates (IRs) of safety outcomes in the absence of vaccination of interest and IRs following the infection targeted by the vaccine, are integral for contextualizing vaccine benefit-risk.. As new respiratory vaccines are developed, contemporaneous IR estimates for outcomes commonly assessed in vaccine safety surveillance are needed in the COVID-19 endemic era.. Methods: This retrospective cohort study used four administrative claims data sources in the United States (HealthVerity Closed Claims, Optum's de-identified Clinformatics® Data Mart, Humana and Medicare Fee-ForService) to estimate IRs for 30 safety outcomes across five organ systems between 1 August 2022 and 31 July 2023. Coagulation:Article Title: Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023. Article Snippet: Background: Background incidence rates (IRs) of safety outcomes in the absence of vaccination of interest and IRs following the infection targeted by the vaccine, are integral for contextualizing vaccine benefit-risk.. As new respiratory vaccines are developed, contemporaneous IR estimates for outcomes commonly assessed in vaccine safety surveillance are needed in the COVID-19 endemic era.. Methods: This retrospective cohort study used four administrative claims data sources in the United States (HealthVerity Closed Claims, Optum's de-identified Clinformatics® Data Mart, Humana and Medicare Fee-ForService) to estimate IRs for 30 safety outcomes across five organ systems between 1 August 2022 and 31 July 2023. Food & Beverages:Article Title: Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023. Article Snippet: Background: Background incidence rates (IRs) of safety outcomes in the absence of vaccination of interest and IRs following the infection targeted by the vaccine, are integral for contextualizing vaccine benefit-risk.. As new respiratory vaccines are developed, contemporaneous IR estimates for outcomes commonly assessed in vaccine safety surveillance are needed in the COVID-19 endemic era.. Methods: This retrospective cohort study used four administrative claims data sources in the United States (HealthVerity Closed Claims, Optum's de-identified Clinformatics® Data Mart, Humana and Medicare Fee-ForService) to estimate IRs for 30 safety outcomes across five organ systems between 1 August 2022 and 31 July 2023. Modification:Article Title: Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023. Article Snippet: Background: Background incidence rates (IRs) of safety outcomes in the absence of vaccination of interest and IRs following the infection targeted by the vaccine, are integral for contextualizing vaccine benefit-risk.. As new respiratory vaccines are developed, contemporaneous IR estimates for outcomes commonly assessed in vaccine safety surveillance are needed in the COVID-19 endemic era.. Methods: This retrospective cohort study used four administrative claims data sources in the United States (HealthVerity Closed Claims, Optum's de-identified Clinformatics® Data Mart, Humana and Medicare Fee-ForService) to estimate IRs for 30 safety outcomes across five organ systems between 1 August 2022 and 31 July 2023. Virus:Article Title: Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023. Article Snippet: Background: Background incidence rates (IRs) of safety outcomes in the absence of vaccination of interest and IRs following the infection targeted by the vaccine, are integral for contextualizing vaccine benefit-risk.. As new respiratory vaccines are developed, contemporaneous IR estimates for outcomes commonly assessed in vaccine safety surveillance are needed in the COVID-19 endemic era.. Methods: This retrospective cohort study used four administrative claims data sources in the United States (HealthVerity Closed Claims, Optum's de-identified Clinformatics® Data Mart, Humana and Medicare Fee-ForService) to estimate IRs for 30 safety outcomes across five organ systems between 1 August 2022 and 31 July 2023. |